IRIS
SOBRERO, Alberto
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 7.427
AS - Asia 3.789
EU - Europa 2.134
SA - Sud America 862
AF - Africa 62
Continente sconosciuto - Info sul continente non disponibili 26
Totale 14.300
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 7.312
SG - Singapore 2.084
UA - Ucraina 836
BR - Brasile 677
CN - Cina 647
VN - Vietnam 320
HK - Hong Kong 318
FI - Finlandia 317
DE - Germania 315
RU - Federazione Russa 167
FR - Francia 127
IE - Irlanda 118
IT - Italia 96
AR - Argentina 89
KR - Corea 87
BD - Bangladesh 68
SE - Svezia 60
CA - Canada 55
TR - Turchia 55
GB - Regno Unito 50
IN - India 45
MX - Messico 26
ID - Indonesia 25
CO - Colombia 24
EC - Ecuador 19
IQ - Iraq 19
PK - Pakistan 19
ZA - Sudafrica 18
CL - Cile 13
UZ - Uzbekistan 13
MA - Marocco 12
AT - Austria 11
PY - Paraguay 10
EU - Europa 9
VE - Venezuela 9
AE - Emirati Arabi Uniti 8
KE - Kenya 8
MY - Malesia 8
SA - Arabia Saudita 8
JP - Giappone 7
PH - Filippine 7
UY - Uruguay 7
BO - Bolivia 6
CR - Costa Rica 6
EG - Egitto 6
IL - Israele 6
PE - Perù 6
PL - Polonia 6
DO - Repubblica Dominicana 5
GT - Guatemala 5
TN - Tunisia 5
AZ - Azerbaigian 4
ES - Italia 4
JO - Giordania 4
KG - Kirghizistan 4
KZ - Kazakistan 4
NL - Olanda 4
NP - Nepal 4
OM - Oman 4
TT - Trinidad e Tobago 4
BE - Belgio 3
BG - Bulgaria 3
JM - Giamaica 3
NI - Nicaragua 3
RO - Romania 3
TH - Thailandia 3
AL - Albania 2
AM - Armenia 2
BH - Bahrain 2
CZ - Repubblica Ceca 2
DZ - Algeria 2
EE - Estonia 2
ET - Etiopia 2
GY - Guiana 2
LB - Libano 2
LT - Lituania 2
QA - Qatar 2
SN - Senegal 2
SV - El Salvador 2
SY - Repubblica araba siriana 2
TW - Taiwan 2
ZW - Zimbabwe 2
BB - Barbados 1
BN - Brunei Darussalam 1
CH - Svizzera 1
CI - Costa d'Avorio 1
DJ - Gibuti 1
DK - Danimarca 1
GR - Grecia 1
HN - Honduras 1
KH - Cambogia 1
KN - Saint Kitts e Nevis 1
KW - Kuwait 1
LC - Santa Lucia 1
LV - Lettonia 1
LY - Libia 1
MK - Macedonia 1
MN - Mongolia 1
PA - Panama 1
PS - Palestinian Territory 1
Totale 14.278
Salva come PNG Salva come JPEG
Città #
Fairfield 935
Ashburn 664
Jacksonville 636
Singapore 582
Woodbridge 438
Wilmington 370
San Jose 360
Seattle 345
Cambridge 329
Houston 321
Hong Kong 314
Chandler 306
Beijing 290
Dearborn 284
Council Bluffs 196
Boardman 141
Princeton 134
Ho Chi Minh City 125
Lauterbourg 117
Dublin 116
Ann Arbor 115
São Paulo 97
Seoul 86
San Diego 80
Los Angeles 75
Hefei 71
Santa Clara 59
Buffalo 58
Hanoi 57
Dallas 41
Izmir 41
Helsinki 40
The Dalles 39
New York 33
Norwalk 32
Ogden 30
Redondo Beach 26
Udine 26
Kunming 22
Da Nang 17
Rio de Janeiro 17
Curitiba 15
Porto Alegre 15
Toronto 15
Belo Horizonte 13
Chicago 13
Haiphong 12
Nanjing 12
Atlanta 11
Brasília 11
Brooklyn 11
Des Moines 10
Guangzhou 10
Mumbai 10
Ottawa 10
Phoenix 10
Tashkent 10
Hải Dương 9
Lahore 9
Nanchang 9
Thái Bình 9
Johannesburg 8
Milan 8
Montreal 8
Nuremberg 8
Philadelphia 8
Santo André 8
Turku 8
Campinas 7
Chennai 7
Guayaquil 7
Jinan 7
Medellín 7
Quito 7
Rome 7
Baghdad 6
Chengdu 6
Denver 6
Dhaka 6
Grafing 6
Manchester 6
Mexico City 6
Montes Claros 6
Nairobi 6
Ninh Bình 6
Orem 6
Pelotas 6
Tokyo 6
Bauru 5
Biên Hòa 5
Bogotá 5
Buenos Aires 5
Cape Town 5
Indaiatuba 5
João Pessoa 5
Juiz de Fora 5
Kuala Lumpur 5
Montevideo 5
Munich 5
Naples 5
Totale 8.532
Salva come PNG Salva come JPEG
Nome #
Fluorouracil in colorectal cancer: a tale of two drugs. Implications for biochemical modulation 291
Enhancement of trimetrexate cytotoxicity in vitro and in vivo by carboxypeptidase G2 262
Evidence for cure by adjuvant therapy in colon cancer: observations based on individual patient data from 20,898 patients on 18 randomized trials 194
Taxane-induced nail changes: incidence, clinical presentation and outcome 176
Adjuvant sequential methotrexate --> 5-fluorouracil vs 5-fluorouracil plus leucovorin in radically resected stage III and high-risk stage II colon cancer 153
DOES BIOMODULATION OF 5-FLUOROURACIL IMPROVE RESULTS? 152
5-fluorouracil modulated by leucovorin, methotrexate and mitomycin: highly effective, low-cost chemotherapy for advanced colorectal cancer 151
Randomized phase III trial comparing biweekly infusional fluorouracil/leucovorin alone or with irinotecan in the adjuvant treatment of stage III colon cancer: PETACC-3 151
Lack of correlation between immunohistochemical expression of E2F-1, thymidylate synthase expression and clinical response to 5-fluorouracil in advanced colorectal cancer 150
Sequential chemotherapy with Paclitaxel plus Cisplatin, followed by Vinorelbine, followed by Gemcitabine in advanced non-small cell lung cancer: an Alpe Adria Thoracic Oncology Multidisciplinary group study (ATOM 001) 150
Alternating bolus and continuous infusion 5-fluorouracil: a strategy to overcome resistance to this fluoropyrimidine in advanced colorectal cancer patients 148
Activity of continuous infusion 5-Fluorouracil in patients with advanced colorectal cancer clinically resistant to bolus 5-Fluorouracil 148
Chemotherapy: which drug and when? 146
Capecitabine/oxaliplatin, a safe and active first-line regimen for older patients with metastatic colorectal cancer: post hoc analysis of a large phase II study 145
Association of progression-free survival, overall survival, and patient-reported outcomes by skin toxicity and KRAS status in patients receiving panitumumab monotherapy 144
5-Fluorouracil may have different mechanisms of action depending on the dose schedule: clinical implications 142
Bevacizumab plus fluorouracil: the value of being part of a developing story 141
EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer 141
Evaluation of clinical efficacy of new medical treatments in advanced colorectal cancer. Results of a workshop organized by the EORTC GITCCG 139
Determinants of sensitivity and resistance to fluoropyrimidines 138
Phase II study of a triplet regimen in advanced colorectal cancer using methotrexate, oxaliplatin and 5-fluorouracil 138
Adjuvant chemotherapy in the treatment of colon cancer: randomized multicenter trial of the Italian National Intergroup of Adjuvant Chemotherapy in Colon Cancer (INTACC) 137
TUMOR MEASUREMENTS ON COMPUTED TOMOGRAPHIC IMAGES OF NON-SMALL CELL LUNG CANCER WERE SIMILAR AMONG CANCER PROFESSIONALS FROM DIFFERENT SPECIALTIES 137
Informed decisions regarding microsatellite instability testing: need for an intention-to-screen analysis 133
Fatigue: a main component of anemia symptomatology 131
Optimal treatment of metastatic colorectal cancer 130
Adjuvant therapy for colon cancer: 12 months, 9 months, 6 months ... why not 3 months? 129
Prognostic role of Ape/Ref-1 subcellular expression in stage I-III breast carcinomas 129
Molecular markers and biological targeted therapies in metastatic colorectal cancer: expert opinion and recommendations derived from the 11th ESMO/World Congress on Gastrointestinal Cancer, Barcelona, 2009 129
Phase IV study of bevacizumab in combination with infusional fluorouracil, leucovorin and irinotecan (FOLFIRI) in first-line metastatic colorectal cancer 129
Metastatic colorectal cancer: integrating irinotecan into combination and sequential chemotherapy 128
Adjuvant treatment of high-risk, radically resected gastric cancer patients with 5-fluorouracil, leucovorin, cisplatin, and epidoxorubicin in a randomized controlled trial 128
Phase II study of NGR-hTNF, a selective vascular targeting agent, in patients with metastatic colorectal cancer after failure of standard therapy 127
Molecular characterization of established human colon carcinoma cell lines (HCT-8) made resistant to 5-fluorouracil by different selection schedules 126
Incremental advance or seismic shift? The need to raise the bar of efficacy for drug approval 126
Current controversies in the adjuvant therapy of colon cancer 125
XELOX (capecitabine plus oxaliplatin): active first-line therapy for patients with metastatic colorectal cancer 125
The management of hepatocellular carcinoma. Current expert opinion and recommendations derived from the 10th World Congress on Gastrointestinal Cancer, Barcelona, 2008 125
Activity of 4'Epi-doxorubicin on normal haemopoietic precursor cells in mice 124
Should adjuvant chemotherapy become standard treatment for patients with stage II colon cancer? For the proposal 123
How uniform are postgraduate training programs in medical oncology in the European Union? 121
Epidermal growth factor receptor gene copy number and clinical outcome of metastatic colorectal cancer treated with panitumumab 120
The potential role of Tomudex in the treatment of advanced colorectal cancer 119
Current strategies to reduce cisplatin toxicity 119
Urgent need for a new staging system in advanced colorectal cancer 119
A randomized trial of 5-fluorouracil alone vs 5-FU and high dose leucovorin in untreated advanced colorectal cancer patients 118
Highlights from the 2008 Gastrointestinal Cancers Symposium 118
Dacarbazine and Fotemustine in Advanced Colorectal Cancer 117
The diagnosis and management of rectal cancer: expert discussion and recommendations derived from the 9th World Congress on Gastrointestinal Cancer, Barcelona, 2007 117
Immunohistochemical quantitation of thymidylate synthase expression in colorectal cancer metastases predicts for clinical outcome to fluorouracil-based chemotherapy 116
Synergism and lack of cross-resistance between short-term and continuous exposure to fluorouracil in human colon adenocarcinoma cells 116
Medical Oncology: IROX as second-line therapy for metastatic colorectal cancer 115
Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer 115
Studies on hemopoietic stem cells in mice treated with testosterone propionate and anticancer drugs 114
Current issues in adjuvant treatment of stage II colon cancer 114
Endpoints in adjuvant treatment trials: a systematic review of the literature in colon cancer and proposed definitions for future trials 114
Irinotecan in combination with new agents 113
Role of oxaliplatin in the treatment of colorectal neoplasms 112
Oral capecitabine vs intravenous 5-fluorouracil and leucovorin: integrated efficacy data and novel analyses from two large, randomised, phase III trials 112
Tamoxifen-induced total alopecia 112
Information given to cancer patients on diagnosis, prognosis and treatment: the clinical oncologist's perspective 111
Current Opinion on Optimal Treatment Choices in First-line Therapy for Advanced or Metastatic Colorectal Cancer: Report From the Adelaide Colorectal Tumour Group Meeting; Stockholm, Sweden; September 2008 111
SCHEDULE-SELECTIVE BIOCHEMICAL MODULATION OF 5-FLUOROURACIL IN ADVANCED COLORECTAL CANCER: A MULTICENTRIC PHASE II STUDY 111
The medical treatment of advanced colorectal 110
Resistance to 5-fluorouracil and 5fluoro 2'deoxyuridine: mechanisms and clinical implications 110
Molecular markers of chemotherapy in advanced colorectal cancer: back to square one 108
The role of 5-fluorouracil (5-FU) reintroduction with irinotecan or oxaliplatin in truly 5-FU-refractory advanced colorectal cancer patients 108
Clinical aspects of drug resistance 104
Scheduling of fluorouracil: a forget-me-not in the jungle of doublets 104
Highly selective drug combinations for human colon cancer cells resistant in vitro to 5-fluoro-2'-deoxyuridine 103
Biochemical determinants of antineoplastic activity of fluoropyrimidines 103
Chemosensitivity of human tumor clonogenic cells simultaneously assayed in agar diffusion chambers and in a two-layer agar culture system 101
Adjuvant treatment of colorectal cancer in the elderly 100
Phase II trial of 5-fluorouracil and the natural l isomer of folinic acid in the treatment of advanced colorectal carcinoma 100
Does chemotherapy prior to liver resection increase the potential for cure in patients with metastatic colorectal cancer? A report from the European Colorectal Metastases Treatment Group 99
Phase II study of 5-fluorouracil + leucovorin and interferon alpha 2 b in advanced colorectal cancer 97
The management of skin reactions in cancer patients receiving epidermal growth factor receptor targeted therapies 97
New directions in the treatment of colorectal cancer: a look to the future 96
Randomised, open-label, phase II trial of paclitaxel, gemcitabine and cisplatin versus gemcitabine and cisplatin as first-line chemotherapy in advanced transitional cell carcinoma of the urothelium 96
Raltitrexed (Tomudex) versus standard leucovorin-modulated bolus 5-fluorouracil: Results from the randomised phase III Pan-European Trial in Adjuvant Colon Cancer 01 (PETACC-1) 96
Combination of surgery and chemotherapy and the role of targeted agents in the treatment of patients with colorectal liver metastases: recommendations from an expert panel Liver Metastases Workshop 95
Sensivity of spleen colony forming units to chronic administration of Bleomycin. Bogliolo G., Massa G., Sobrero A., and Pannacciulli I. British Journal of Cancer 40: 489, 1979. 95
THE ROLE OF METHOTREXATE IN THE TREATMENT OF GESTIONAL TROPHOBLASTIC NEOPLASM 94
schedule specific biochemical modulation of 5-fluorouracil in advanced colorectal cancer : A randomized study 91
Prospective randomized trial comparing fluorouracil versus doxifluorouridine for the treatment of advanced colorectal cancer 91
PROTOCOLLI DI CHEMIOTERAPIA ANTINEOPLASTICA 90
Improved therapeutic index of cisplatin with procaine HCl 90
Surgical resection of gastrointestinal stromal tumor after treatment with imatinib: clinical case 88
Capecitabine versus bolus fluorouracil plus leucovorin (folinic acid) as adjuvant chemotherapy for patients with Dukes' C colon cancer : economic evaluation in an Italian NHS setting 85
The clinical management of early and advanced colorectal cancer 84
The handling of metastatic colorectal cancer 83
Mechanisms of action of 5-8-dideazaisofolic acid and other quinazoline antifols in human colon carcinoma cells in vitro 83
Decreased folylpolyglutamate synthetase expression : a novel mechanism of fluorouracil resistance 82
Uptake and metabolism of 5-8-dideazaisofolic acid in human colon cancer cells 82
Very high dose cisplatinum (450 mg/sqm) in an infant with rhabdomyosarcoma 81
Defective facilitated diffusion of nucleosides, a primary mechanism of resistance to 5-fluoro-2'-deoxyuridine 81
Drug resistant cells as targets for new therapies 80
Sequence dependent enhancement of HCT-8 cell kill by trimetrexate and fluoropyrimidines: implications for these interactions 80
Comparison of in vitro drug sensitivity by inhibition of tritium release from [5-3H]-2'-deoxyuridine and a clonogenic assay 77
LE ANEMIE 77
Totale 11.936
Salva come PNG Salva come JPEG
Categoria #
all - tutte 53.585
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 53.585
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022717 0 0 0 75 20 31 43 66 15 165 137 165
2022/2023718 138 42 9 76 65 227 0 39 93 7 9 13
2023/2024162 29 8 3 3 16 24 1 11 43 0 0 24
2024/20252.497 38 154 207 71 31 63 89 83 180 297 507 777
2025/20263.541 210 518 340 503 459 255 293 116 168 294 260 125
2026/2027855 64 212 320 259 0 0 0 0 0 0 0 0
Totale 14.300